The model currently exhibits extremely high precision.
When the model predicts that a compound is active, it is rarely incorrect. This behavior makes it useful for reducing false positives during early-stage virtual screening.
However, recall remains moderate, meaning some genuinely active compounds may not be identified.
Current development efforts are focused on improving recall while maintaining strong precision.
Regression Task (Potency Prediction)
Metric
Score
RMSE
1.099
MAE
0.723
R²
-0.235
Pearson r
0.404
Spearman ρ
0.578
Interpretation
The regression component remains experimental.
While the model demonstrates moderate ranking capability (Spearman correlation 0.578), absolute potency prediction is currently unreliable.
The model can often distinguish stronger interactions from weaker ones, but exact pXC50 values should not be interpreted as experimentally accurate measurements.
For the current release:
✅ Suitable for relative ranking
⚠️ Not suitable for precise potency estimation
Future work will focus heavily on improving regression performance through larger datasets, improved loss functions, and multi-task optimization.
DTI-BioMedBERT
Classification Task (Activity Prediction)
Metric
Score
Accuracy
0.925
Precision
0.560
Recall
0.593
F1 Score
0.576
ROC-AUC
0.903
Interpretation
The DTI-BioMedBERT checkpoint demonstrates strong classification performance with a ROC-AUC of 0.903, indicating effective discrimination between active and inactive drug–target pairs.
Compared with DTI-LLM, it provides a more balanced precision–recall tradeoff and is optimized specifically for activity prediction.
Recommended use cases include:
✅ Binary DTI classification
✅ Large-scale virtual screening
✅ Activity prediction benchmarks
✅ Fast inference workflows
Choosing a Model
Use Case
Recommended Model
Activity Prediction Only
DTI-BioMedBERT
Activity + Potency Prediction
DTI-LLM
Fast Screening
DTI-BioMedBERT
Potency Ranking
DTI-LLM
LLM-Based Biomedical Research
DTI-LLM
Highest ROC-AUC Classification
DTI-BioMedBERT
Current Development Status
These models are actively being developed.
Planned improvements include:
Larger and more diverse training datasets
Additional target protein coverage
Improved regression accuracy
Better calibration of confidence scores
Multi-stage fine-tuning strategies
Retrieval-augmented biomedical context
Expanded benchmark evaluation
Performance metrics and model behavior may change significantly between releases.